Entrada Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in establishing a class of medicines, which engages intracellular targets. Its Endosomal Escape Vehicle (EEV)-therapeutics are designed to enable the delivery of a range of therapeutics into a variety of organs and tissues, resulting in an improved therapeutic index. The Company is advancing a robust development portfolio of genetic medicines for the potential treatment of neuromuscular and inherited retinal diseases, among others. The Company is focused on the development of EEV therapeutics for rare neuromuscular diseases, including Duchenne muscular dystrophy (DMD) and myotonic dystrophy type 1 (DM1). It has partnered to develop a clinical-stage program, VX-670, for myotonic dystrophy type 1. The Company has advanced two ocular programs into lead optimization for the potential treatment of inherited retinal diseases.
Back to dashboard
Company Information
About this company
Key people
Kush M. Parmar
Independent Chairman of the Board
Nathan J. Dowden
President, Chief Operating Officer
Dipal Doshi
Chief Executive Officer, Director
Kory James Wentworth
Chief Financial Officer, Treasurer
Natarajan Sethuraman
President of Research and Development
Peter S. Kim
Director
Gina Chapman
Independent Director
Mahalakshmi Radhakrishnan
Independent Director
Mary T. Thistle
Independent Director
Click to see more
Key facts
- Shares in issue38.94m
- EPICTRDA
- ISINUS29384C1080
- LocationUnited States
- SectorHealthcare
- IndustryBiotechnology & Drugs
- Market cap$170.15m
- Employees152
- ExchangeNASDAQ
- Index
- Website
Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.